Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary supplement product. It sells its products through e-commerce website and distributors. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.
Research context
Provexis plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Provexis plc is currently in a long term uptrend where the price is trading 9.5% above its 200 day moving average.
From a valuation standpoint, the stock is 89.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 48.2.
Provexis plc's total revenue sank by 0.0% to $111K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-75K since the same quarter in the previous year.
Finally, its free cash flow grew by 11.4% to $-68K since the same quarter in the previous year.
Based on the above factors, Provexis plc gets an overall score of 3/5.